DAVID ALLENBERG contact KATZENSTEIN
Affiliation: Stanford University
- Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisBarbara A Rath
Department of Pediatrics, Division of Pneumonology Immunology, Charite University Medical Center, Berlin, Germany
BMC Infect Dis 13:1. 2013..The study was conducted in the first cohort of children gaining access to structured ART in Peru...
- Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort studyZiad El-Khatib
Nordic School of Public Health NHV, Gothenburg, Sweden
BMC Public Health 11:88. 2011..We assessed risk factors for incomplete adherence among a cohort of HIV-infected women initiating ART and examined associations between adherence and virologic response to ART...
- Genotype, phenotype, and virtual phenotype: who needs what and why?David A Katzenstein
Stanford University Medical Center, Infectious Disease, S 156, SUMC, Stanford, California 94305 5107, USA
J Int Assoc Physicians AIDS Care (Chic) 2:140-6. 2003
- Diversity, drug resistance, and the epidemic of subtype C HIV-1 in AfricaDavid Katzenstein
Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
J Infect Dis 194:S45-50. 2006....
- Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapineEsther J Lee
Center for AIDS Research, Division of Infectious Disease, Stanford University School of Medicine, Stanford, CA 94305, USA
J Infect Dis 192:1260-4. 2005..In 20 paired BM and plasma samples, 65% of BM and 50% of plasma RT sequences had NNRTI-resistance mutations, with divergent mutation patterns...
- Genetic correlates of efavirenz hypersusceptibilityNancy S Shulman
Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
AIDS 18:1781-5. 2004..NNRTI hypersusceptibility has been associated with improved outcomes to NNRTI-based therapy...
- Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assaysNancy S Shulman
Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
J Acquir Immune Defic Syndr 39:78-81. 2005..In fact, there was a report that a commercial multicycle assay did not readily detect hypersusceptibility...
- HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypesSoo Yon Rhee
Division of Infectious Disease, Stanford University, Stanford, California, USA
AIDS 20:643-51. 2006..As additional non-B sequences from persons with well-characterized antiretroviral treatment histories have become available, the program has been extended to subtypes A, C, D, F, G, CRF01, and CRF02...
- Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisEran Bendavid
Center for Health Policy and the Center for Primary Care and Outcomes Research, School of Medicine, Stanford University, 117 Encina Commons, Stanford, CA 94305, USA
Arch Intern Med 168:1910-8. 2008..Although the number of infected persons receiving highly active antiretroviral therapy (HAART) in low- and middle-income countries has increased dramatically, optimal disease management is not well defined...
- Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysisEran Bendavid
Department of Medicine, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA 94305, USA
J Acquir Immune Defic Syndr 52:106-13. 2009..The effectiveness and cost-effectiveness of increasing the number of antiretroviral regimens is unknown...
- Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patientsMark A Winters
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305, USA
J Infect Dis 188:537-40. 2003..These results show that ddI continues to provide activity against viruses with the M184V/I mutation and suggest that the presence of the M184V/I mutation should not preclude the use of ddI in nucleoside-experienced patients...
- High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentElizabeth R Johnston
Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94035, USA
J Virol 77:7682-8. 2003..These results suggest that CXCR4-tropic viruses are present within the quasispecies of patients infected with subtype C virus and that antiretroviral treatment may create an environment for the emergence of CXCR4 tropism...
- Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patientsNancy S Shulman
Stanford University School of Medicine, California 94305, USA
J Acquir Immune Defic Syndr 31:121-7. 2002..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
- HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapyRami Kantor
Division of Infectious Diseases and AIDS Research, Stanford University, California 94305, USA
AIDS Res Hum Retroviruses 18:1407-13. 2002..Comparison of subtype C RT and protease sequences with a large database of subtype B sequences identified subtype C-specific polymorphisms and candidate drug resistance mutations...
- Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugsDavid A Katzenstein
Center for AIDS Research, Stanford, CA, USA
AIDS 17:821-30. 2003..To evaluate phenotypic drug susceptibility and non-nucleoside reverse transcriptase inhibitor hypersusceptibility as predictors of the time to virological failure...
- Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationRami Kantor
Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
PLoS Med 2:e112. 2005..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
- The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in ZimbabweAvinash K Shetty
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA
Int J STD AIDS 16:755-9. 2005..This programme is being implemented at several urban and rural MTCT sites in Zimbabwe and can serve as a model for other resource-poor countries...
- Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 monthsAvinash K Shetty
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
J Acquir Immune Defic Syndr 34:482-90. 2003..A phase 3 study is planned to assess the efficacy of OD infant NVP regimen to prevent breast-feeding HIV-1 transmission...
- Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
JAMA 288:222-35. 2002..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
- More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175Nancy S Shulman
J Infect Dis 196:328-9; author reply 329-30. 2007
- Laboratory indicators of mastitis are not associated with elevated HIV-1 DNA loads or predictive of HIV-1 RNA loads in breast milkSoren Gantt
Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
J Infect Dis 196:570-6. 2007..An improved understanding of the relationship between indicators of inflammation and HIV-1 loads in breast milk could improve MTCT prevention strategies...
- Cytomegalovirus and Epstein-Barr virus in breast milk are associated with HIV-1 shedding but not with mastitisSoren Gantt
Departments of Pediatrics, Seattle Children s Hospital Research Institute, 1900 Ninth Avenue, Seattle, WA 98101, USA
AIDS 22:1453-60. 2008..Bacterial infections may cause clinical mastitis, but whether other copathogens common in HIV-1 infection are associated with subclinical mastitis or HIV-1 shedding is unknown...
- Maternal HIV-1 antibody and vertical transmission in subtype C virus infectionHugo Guevara
Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, CA, U S A
J Acquir Immune Defic Syndr 29:435-40. 2002..22 and OR = 2.52, respectively. No correlation between NA to homologous HIV-1 subtype C virus and MTCT was found. BA to V3 peptides may provide a rapid inexpensive method that can be used to determine the risk of HIV-1 MTCT...
- Association of high HIV-1 RNA levels and homozygosity at HLA class II DRB1 in adults coinfected with Mycobacterium tuberculosis in Harare, ZimbabweLynn S Zijenah
Department of Immunology, University of Zimbabwe Medical School, Harare, Zimbabwe
Hum Immunol 63:1026-32. 2002..The observed decreased virus load in HLA-DRB-1 heterozygotes may be due to a better control of M. tb. infection in the context of HIV-1 disease...
- Editorial comment: a plethora or options in multidrug-resistant HIV-1 infectionDavid A Katzenstein
AIDS Read 18:478-9. 2008
- Editorial comment: interpretation of resistance tests remains complexDavid A Katzenstein
AIDS Read 13:141. 2003
- Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
JAMA 296:827-43. 2006..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
- Of molecules, macaques and global AIDSDavid A Katzenstein
AIDS 20:1065-6. 2006
- Antiretroviral treatment in resource-poor settings: clinical research prioritiesMiriam Rabkin
Department of Medicine, Columbia University, New York, USA
Lancet 360:1503-5. 2002
- Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapyCamlin Tierney
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
J Infect Dis 187:144-8. 2003..03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008)...
- Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 yearsLynn S Zijenah
Department of Immunology, Division of Infectious Diseases, College of Health Sciences, University of Zimbabwe, Harare
J Acquir Immune Defic Syndr 39:391-4. 2005..These evaluated parameters were not statistically different between infants aged 0-6 and 7-18 months. The ultrasensitive p24 antigen assay is a useful diagnostic test for detection of HIV-1 infection among infants aged 0-18 months...
- Editorial comment: resistance testing--an integral part of HIV managementDavid A Katzenstein
AIDS Read 13:36. 2003
- Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
JAMA 292:251-65. 2004..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
- Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenzRonald J Bosch
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA
AIDS 17:2395-6. 2003
- Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levelsDavid M Simpson
Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1052, New York, NY 10029, USA
AIDS 16:407-12. 2002..To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP)...
- Infant feeding practices of HIV-infected and uninfected women in ZimbabweDanielle Gottlieb
University of California, San Francisco School of Medicine, San Francisco, California, USA
AIDS Patient Care STDS 18:45-53. 2004..Knowledge of HIV status may influence infant feeding decisions and reveal an urgent need to address infant feeding practices of pregnant women in Zimbabwe...
- Drug Resistance and Pathogenesis in Subtype C HIV-1David Katzenstein; Fiscal Year: 2008..The aim is to study the pathogenesis of subtype C HIV-1 in women and infants after ARV including SD NVP to optimize clinical benefits of ARV treatment and prevention of MTCT. ..